Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Feb 15, 2026; 18(2): 113922
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.113922
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.113922
Clinical efficacy of Fuzheng Jiedu Xiaoyong granules in advanced colorectal cancer (spleen deficiency and stasis toxin syndrome)
Hai-Yun Qin, Second Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang 110031, Liaoning Province, China
Hai-Yun Qin, Dan Mi, Feng-Zhen Li, Xin Hu, Department of Oncology, The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110034, Liaoning Province, China
Zheng Li, Department of Integrated Traditional Chinese and Western Medicine, Liaoning Cancer Hospital & Institute, Shenyang 110847, Liaoning Province, China
Pei-Wei Cong, Teaching Experiment Center, Liaoning University of Traditional Chinese Medicine, Shenyang 110031, Liaoning Province, China
Guo-Xin Li, Guoyi Hall, The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang 110034, Liaoning Province, China
Author contributions: Qin HY and Li GX designed the research study; Qin HY, Li Z, Li FZ, Hu X and Mi D performed the research; Qin HY, Li Z, Cong PW and Mi D contributed new reagents and analytic tools; Qin HY and Mi D analyzed the data and wrote the manuscript; all authors have read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine [Approval No. 2023(XS)-003-02(FS)].
Clinical trial registration statement: This study is registered at http://itmctr.ccebtcm.org.cn. The registration identification number is ITMCTR2025002274.
Informed consent statement: All study participants provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All authors of this manuscript declare that they have no conflicts of interest in this study.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Data sharing statement: Technical appendix, statistical code, and dataset were available from the first author at hyman_825@163.com.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Guo-Xin Li, PhD, Chief Physician, Professor, Guoyi Hall, The Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, No. 60 Huanghe North Street, Huanggu District, Shenyang 110034, Liaoning Province, China.
Received: October 14, 2025
Revised: November 21, 2025
Accepted: December 18, 2025
Published online: February 15, 2026
Processing time: 111 Days and 17.4 Hours
Revised: November 21, 2025
Accepted: December 18, 2025
Published online: February 15, 2026
Processing time: 111 Days and 17.4 Hours
Core Tip
Core Tip: The combination of Fuzheng Jiedu Xiaoyong granules (FZJDXYG) with first-line therapy for advanced colorectal cancer (CRC) demonstrates significant clinical efficacy with minimal adverse effects. It can effectively modulate immune dysfunction and improve patients’ quality of life. A parallel, randomized, controlled trial confirmed the significant efficacy and high safety of FZJDXYG in treating advanced CRC patients. Moreover, FZJDXYG significantly increased CD4+ T cell abundance, reduced CD8+ T cell abundance, and increased the CD4+/CD8+ ratio in patients, with significant differences before and after treatment, as well as between the treatment and control group.